GRIN Therapeutics Expands Phase 3 Beeline Study for GRIN-NDD in Europe
GRIN Therapeutics has initiated its Phase 3 Beeline study in Europe, expanding its global clinical program for radiprodil, a treatment for GRIN-related neurodevelopmental disorder (GRIN-NDD). The study aims to evaluate the efficacy and safety of radiprodil, targeting NMDA receptor overactivation. The European expansion includes sites in Belgium, France, Germany, and other countries, building on previous studies in the US and UK. This marks a significant step in developing a targeted therapy for GRIN-NDD, a complex neurodevelopmental condition.